[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3616 Introduced in House (IH)]







109th CONGRESS
  1st Session
                                H. R. 3616

  To expand the research, prevention, and awareness activities of the 
 National Institute of Diabetes and Digestive and Kidney Diseases and 
    the Centers for Disease Control and Prevention with respect to 
                      inflammatory bowel disease.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             July 29, 2005

   Mrs. Kelly (for herself, Mr. Cardin, Mr. Jackson of Illinois, Ms. 
    Schakowsky, Mr. Weiner, Mr. McNulty, Mr. Moran of Virginia, Mr. 
  Hinchey, Ms. Kaptur, Mr. Taylor of Mississippi, Ms. Jackson-Lee of 
 Texas, Mr. Berry, and Mr. Cunningham) introduced the following bill; 
       which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
  To expand the research, prevention, and awareness activities of the 
 National Institute of Diabetes and Digestive and Kidney Diseases and 
    the Centers for Disease Control and Prevention with respect to 
                      inflammatory bowel disease.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Inflammatory Bowel Disease Research 
Act''.

SEC. 2. FINDINGS.

    The Congress finds as follows:
            (1) Crohn's disease and ulcerative colitis are serious 
        inflammatory diseases of the gastrointestinal tract.
            (2) Crohn's disease may occur in any section of the 
        gastrointestinal tract but is predominately found in the lower 
        part of the small intestine and the large intestine. Ulcerative 
        colitis is characterized by inflammation and ulceration of the 
        innermost lining of the colon. Complete removal of the colon in 
        patients with ulcerative colitis can potentially alleviate and 
        cure symptoms.
            (3) Because Crohn's disease and ulcerative colitis behave 
        similarly, they are collectively known as inflammatory bowel 
        disease. Both diseases present a variety of symptoms, including 
        severe diarrhea; abdominal pain with cramps; fever; and rectal 
        bleeding. There is no known cause of inflammatory bowel 
        disease, or medical cure.
            (4) It is estimated that up to 1,400,000 people in the 
        United States suffer from inflammatory bowel disease, 30 
        percent of whom are diagnosed during their childhood years.
            (5) Children with inflammatory bowel disease miss school 
        activities because of bloody diarrhea and abdominal pain, and 
        many adults who had onset of inflammatory bowel disease as 
        children had delayed puberty and impaired growth and have never 
        reached their full genetic growth potential.
            (6) Inflammatory bowel disease patients are at high risk 
        for developing colorectal cancer.
            (7) The total annual medical costs for inflammatory bowel 
        disease patients is estimated at more than $2,000,000,000.

SEC. 3. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY 
              DISEASES; INFLAMMATORY BOWEL DISEASE RESEARCH EXPANSION.

    (a) In General.--The Director of the National Institute of Diabetes 
and Digestive and Kidney Diseases shall expand, intensify, and 
coordinate the activities of the Institute with respect to research on 
inflammatory bowel disease, with particular emphasis on the following 
areas:
            (1) Genetic research on susceptibility for inflammatory 
        bowel disease, including the interaction of genetic and 
        environmental factors in the development of the disease.
            (2) Research targeted to increase knowledge about the 
        causes and complications of inflammatory bowel disease in 
        children.
            (3) Animal model research on inflammatory bowel disease, 
        including genetics in animals.
            (4) Clinical inflammatory bowel disease research, including 
        clinical studies and treatment trials.
            (5) Expansion of the Institute's Inflammatory Bowel Disease 
        Centers program with a focus on pediatric research.
            (6) Other research initiatives identified by the scientific 
        document entitled ``Challenges in Inflammatory Bowel Disease'' 
        and the research agenda for pediatric gastroenterology, 
        hepatology and nutrition entitled ``Chronic Inflammatory Bowel 
        Disease''.
    (b) Authorization of Appropriations.--
            (1) In general.--For the purpose of carrying out subsection 
        (a), there are authorized to be appropriated $75,000,000 for 
        fiscal year 2006, $85,000,000 for fiscal year 2007, and 
        $100,000,000 for fiscal year 2008.
            (2) Reservation.--Of the amounts authorized to be 
        appropriated under paragraph (1), not more than 20 percent 
        shall be reserved for the training of qualified health 
        professionals in biomedical research focused on inflammatory 
        bowel disease, including pediatric investigators.

SEC. 4. CENTERS FOR DISEASE CONTROL AND PREVENTION; NATIONAL 
              INFLAMMATORY BOWEL DISEASE ACTION PLAN.

    (a) In General.--
            (1) Preparation of plan.--The Director of the Centers for 
        Disease Control and Prevention, in consultation with the 
        inflammatory bowel disease community, shall prepare a 
        comprehensive plan to address the burden of inflammatory bowel 
        disease in both adult and pediatric populations (which plan 
        shall be designated by the Director as the ``National 
        Inflammatory Bowel Disease Action Plan'').
            (2) Report to congress.-- Not later than 12 months after 
        the date of the enactment of this Act, the Director of the 
        Centers for Disease Control and Prevention shall submit the 
        Plan referred to in paragraph (1) to the Committee on Energy 
        and Commerce and the Committee on Appropriations in the House 
        of Representatives and to the Committee on Health, Education, 
        Labor and Pensions and the Committee on Appropriations in the 
        Senate.
    (b) Content.--
            (1) In general.--The National Inflammatory Bowel Disease 
        Action Plan shall address strategies for determining the true 
        prevalence of inflammatory bowel disease in the United States, 
        and the unique demographic characteristics of the patient 
        community through the expansion of appropriate epidemiological 
        activities.
            (2) Certain requirements.-- The Plan referred to in 
        paragraph (1) shall--
                    (A) focus on strategies for increasing awareness 
                about inflammatory bowel disease within the general 
                public and the health care community in order to 
                facilitate more timely and accurate diagnoses; and
                    (B) address mechanisms designed to prevent the 
                progression of the disease and the development of 
                complications, such as colorectal cancer, and other 
                strategies and activities as deemed appropriate.
    (c) Authorization of Appropriations.--For the purpose of carrying 
out this section, there is authorized to be appropriated $750,000 for 
fiscal year 2006.
                                 <all>